<DOC>
	<DOCNO>NCT02452268</DOCNO>
	<brief_summary>This Phase 1 trial define side effect profile maximum tolerate dose ( MTD ) hetIL-15 , subject advance metastatic cancer . hetIL-15 synthetic version protein normally make human body stimulate white blood cell may able boost number activity cell attack cancer</brief_summary>
	<brief_title>A Study Subcutaneous Recombinant Human hetIL-15 ( IL15/sIL-15Ra ) Adults With Metastatic Cancers</brief_title>
	<detailed_description>This Phase 1 , single center clinical trial . The design open label , single arm , dose escalation subject advance metastatic cancer fail standard treatment curative palliative measure either exist associate survival advantage . The study population involve male female subject , least 18 year old confirm diagnosis cancer metastatic refractory inappropriate standard medical treatment .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm solid tumor malignancy metastatic unresectable progress least 1 prior therapy standard curative palliative measure exist associate minimal subject survival benefit . Evaluable measurable disease , define Response Evaluation Criteria Solid Tumors ( RECIST ) . 2 . Recovered ≤ grade 1 NCI CTCAE version 4.0 toxicity prior chemotherapy biologic therapy administer 4 week earlier . 3 . Subjects bisphosphonates cancer hormone therapy prostate cancer may continue therapy . However , subject prostate cancer must confirm metastatic disease progress despite hormonal therapy produce castrate level testosterone . 4 . Age ≥18 year . 5 . ECOG performance status ≤1 ( Karnofsky ≥70 % ) . 6 . Normal organ marrow function : leukocyte ≥3,000/mcL absolute neutrophil count ( ANC ) ≥1,500/mcL platelet ≥100,000/mcL total bilirubin within normal institutional limit AST/ALT ≤2.5 × ULN creatinine &lt; 1.5 × institutional ULN OR creatinine clearance ≥60 mL/min/1.73 m2 subject serum creatinine level &gt; 1.5 × high ULN . 7 . DLCO/VA FEV1 ≥ 50 % predicted PFTs . 8 . Subjects inactive central nervous system ( CNS ) metastasis eligible.. 9 . Women childbearing potential men must agree use adequate contraception prior study entry , treatment portion study 4 month completion hetIL15 administration . 10 . Able provide write informed consent . 11 . Life expectancy &gt; 3 month . 1 . Prior IL15 treatment cytotoxic therapy , immunotherapy , radiotherapy , major surgery , antitumor vaccine monoclonal antibody 4 week prior checkpoint inhibitor antiCTLA4 anti PD1/PDL1 nitrosoureas mitomycin C 6 week prior C1D1 . 2 . Primary brain cancer active CNS metastasis exclude clinical trial 3 . History allergic reaction attribute compound similar chemical biologic composition hetIL15 . 4 . Concurrent anticancer therapy ( include investigational agent ) exception hormone therapy prostate cancer . 5 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , cognitive impairment , active substance abuse , psychiatric illness/social situation , view Investigator , would preclude safe treatment ability give inform consent limit compliance study requirement . 6 . HIV positive patient . 7 . Positive hepatitis B C serology . 8 . History severe asthma absolute requirement chronic inhale corticosteroid medication . 9 . History autoimmune disease , exception autoimmune event associate prior ipilimumab ( antiCTLA4 ) therapy completely resolve 4 week prior C1D1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>